1. Home
  2. TYRA vs VVX Comparison

TYRA vs VVX Comparison

Compare TYRA & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$30.63

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo V2X Inc.

VVX

V2X Inc.

HOLD

Current Price

$83.60

Market Cap

2.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
VVX
Founded
2018
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
TYRA
VVX
Price
$30.63
$83.60
Analyst Decision
Strong Buy
Hold
Analyst Count
11
8
Target Price
$47.50
$69.88
AVG Volume (30 Days)
725.7K
481.1K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
126.85
EPS
N/A
0.60
Revenue
N/A
$4,480,038,000.00
Revenue This Year
N/A
$7.81
Revenue Next Year
N/A
$5.84
P/E Ratio
N/A
$139.97
Revenue Growth
N/A
3.65
52 Week Low
$9.96
$46.27
52 Week High
$40.65
$91.80

Technical Indicators

Market Signals
Indicator
TYRA
VVX
Relative Strength Index (RSI) 44.97 64.77
Support Level $29.68 $66.71
Resistance Level $30.70 $91.80
Average True Range (ATR) 1.71 2.65
MACD -0.21 1.11
Stochastic Oscillator 16.17 85.05

Price Performance

Historical Comparison
TYRA
VVX

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: